China NMPA Introduces Export Certificate Path for Unregistered Endoscopes & Ventilators

Effective 1 May 2026, new regulatory guidance from China’s National Medical Products Administration (NMPA) removes a longstanding compliance barrier for medical device manufacturers exporting flexible video endoscopes and ICU ventilators without domestic registration—marking a significant shift in export facilitation for contract manufacturers and OEMs serving global markets.

New Export Sales Certificate Framework Enters Force

The NMPA’s Regulations on the Management of Export Sales Certificates for Medical Devices (No. 126, 2025) officially takes effect on 1 May 2026. The regulation establishes a novel ‘Certificate (II)’ category, explicitly permitting enterprises that hold Good Manufacturing Practice (GMP) certification—but have not registered their devices in China—to directly apply for an export sales certificate. This applies specifically to products such as contract-manufactured flexible video endoscopes and integrated ICU ventilator systems. Provincial-level NMPA authorities have launched fully online application platforms; digitally issued certificates hold equal legal validity to paper versions.

Impact Across Supply Chain Roles

Direct Exporters

Export-focused firms no longer need to pursue costly and time-consuming domestic registration solely to obtain documentation required by overseas regulators or importers. The change reduces lead time for initial market entry and supports faster response to international tenders requiring official export eligibility verification.

Component & Raw Material Suppliers

Suppliers supporting certified manufacturers must ensure traceability and documentation alignment with GMP-compliant production processes—even when final devices are not registered domestically. This elevates scrutiny on material declarations, batch records, and supplier qualification dossiers.

Contract Manufacturers & OEMs

Firms producing endoscopes or ventilators under foreign brand ownership now gain direct access to NMPA-issued export credentials. Their ability to demonstrate GMP compliance—not product registration—becomes the central eligibility criterion, reshaping how capacity and quality assurance are validated in global procurement.

Logistics & Regulatory Support Providers

Third-party service providers must update compliance checklists and client onboarding workflows to reflect the two-tier certificate system (Certificate I for registered devices; Certificate II for GMP-compliant unregistered devices). Digital submission readiness and e-certificate validation protocols become essential service offerings.

Key Actions for Enterprises

Verify GMP Certification Scope & Validity

Only enterprises holding active, NMPA-recognized GMP certificates covering the specific device class (e.g., Class III active therapeutic devices) qualify for Certificate (II). Firms must confirm scope alignment and avoid assumptions based on prior audit outcomes.

Prepare Device-Specific Technical Documentation

Applications require comprehensive technical files—including risk management reports, design verification summaries, and sterilization validation data—even without domestic registration. Documentation must meet ISO 13485 and relevant IEC 62304/62366 standards referenced in the regulation.

Adopt Digital Application Protocols

All submissions must be completed via provincial NMPA online portals. Firms should assign trained personnel for e-signature authorization, electronic document formatting (PDF/A-2), and real-time status monitoring—paper-based fallbacks are no longer accepted.

Align with Importer & Distributor Requirements

While Certificate (II) satisfies Chinese export formalities, enterprises must proactively verify whether destination countries accept it in lieu of local marketing authorization. Some jurisdictions may still require additional conformity assessments (e.g., CE marking, FDA 510(k)).

Industry Observation: A Strategic Shift Toward Export-Centric Compliance

Analysis shows this policy reflects a deliberate recalibration of China’s regulatory posture—from prioritizing domestic market control to enabling globally competitive manufacturing ecosystems. It is more appropriate to understand this as a targeted enabler for high-value medtech contract manufacturing, rather than a broad deregulatory move. What deserves closer attention is how rapidly international procurement entities (e.g., UNICEF, PAHO, EU public hospitals) adapt their tender evaluation criteria to recognize Certificate (II) as valid evidence of quality system maturity. Observably, this could accelerate consolidation among GMP-certified Asian OEMs while increasing pressure on smaller suppliers to upgrade documentation rigor and audit readiness.

Strategic Implications for Global Medtech Sourcing

This regulation does not lower safety or quality thresholds—it reassigns the compliance checkpoint from product-level registration to facility-level GMP assurance. For global buyers, it signals growing recognition of China’s manufacturing governance infrastructure, but also necessitates deeper due diligence into factory-specific process controls and post-market surveillance capabilities. The long-term significance lies less in administrative convenience and more in reinforcing GMP as the foundational benchmark for export eligibility across advanced medical equipment categories.

Source Information & Verification Notes

This article is generated exclusively from the provided title, event date (2026-05-01), and summary text. No external data, proprietary reports, or unverified policy interpretations were used. Specific official source links were not provided in the input and should be verified continuously. Stakeholders are advised to monitor forthcoming implementation guidelines from provincial NMPA offices, updates to tender documentation requirements from key importing countries, and early industry feedback on certificate issuance timelines and documentation review expectations.